Daiichi, Sankyo Deal Will Fend Off Foreign Competition In Japan, Build In U.S.
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daiichi/Sankyo merger will build domestic position, broaden U.S. market penetration. Daiichi Sankyo will be the second largest Japanese pharmaceutical company based on domestic sales. Combined global sales force is 2,200 reps, with plans to expand. U.S. sales force is 850 reps. Integration should be complete by April 2007
You may also be interested in...
Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
Japanese pharma firms are changing the long-standing practice of out-licensing products in the U.S., with maturing U.S. operations now directly developing more than a dozen drugs in or near Phase III.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product